FDA’s Unapproved-Use Communication Rules Prompt First Amendment Worries

An FDA memo outlining restrictions on communications over unapproved uses could restrict the flow of important information, and conflict with a company’s freedom of speech, say drugmakers and industry groups.
Source: Drug Industry Daily